The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes, STAT reports. Some are optimistic that the pathway will clarify the CMS coverage process. Matt Wetzel, head of the Medtech practice, acknowledged that this is not a “blockbuster change.” He continued, “but it’s an acknowledgement that there has to be earlier discussion, and, especially for the most innovative breakthrough technology, there’s a push and a desire to get that to the market quickly."